 LEEDS, England--BUSINESS WIRE--4D pharma plc AIM: DDD, a pharmaceutical company leading the development of Live Biotherapeutic products LBPs - a novel class of drug derived from the microbiome, today announces that the United States Securities and Exchange Commission SEC has declared effective its registration statements on Form F-4 with respect to the issuance of 4D pharma American Depositary Shares ADSs to the shareholders of Longevity Acquisition Corporation NASDAQ: LOAC L 